We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Onzima Ventures | LSE:ONZ | London | Ordinary Share | GB00BYQCDH57 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.25 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 1.25 | GBX |
Onzima Ventures (ONZ) Share Charts1 Year Onzima Ventures Chart |
|
1 Month Onzima Ventures Chart |
Intraday Onzima Ventures Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 04/6/2021 | 16:02 | Onzima - the old Ultima Networks | 841 |
| 04/5/2017 | 11:27 | Buy ONZ to get N4 Pharma's multi-blockuster potential | 582 |
| 02/8/2016 | 18:26 | Large Healthcare Company | 28 |
| 02/8/2016 | 17:14 | Ј500m+ Company | 462 |
| 02/8/2016 | 16:55 | Ј2.6m mcap! | 16 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 13/4/2017 08:14 by curlly Am I being thick or have they raised money at 7p which is about 5 times the share price. |
Posted at 06/4/2017 08:55 by emc01 Does anyone know what this would mean for existing shareholders please? It’s from the 18th April 2017 – Notice of Annual General Meeting, on the Onzima Ventures website:Authority to allot shares and waiver of pre-emption rights (resolutions 4and 5)The Directors seek authority to allot up to a maximum of 181,956,558 ordinary shares. Further, in order to retain some flexibility at this stage in the Company’s development, the Directors seek power to allot 181,956,558 equity securitieswholly for cash other than on a pre-emptive basis to current shareholders pro-rata to their existing holdings. This amount represents 100% of the issued ordinary share capital as at 24th March 2017. These authorities will continue in force until the AGM to be held in 2018 or 30 June 2018, whichever is the earlier. |
Posted at 17/1/2017 10:43 by someuwin 17 January 2017Onzima Ventures plc ("Onzima" or the "Company") Proposed Acquisition, Strategic Update and Appointment of Nominated Adviser and Broker Onzima is pleased to announce that it has agreed in principle terms conditionally to acquire the 51 per cent. of the issued shares of N4 Pharma Limited ("N4 Pharma") which it does not already own (the "Proposed Acquisition"). The consideration for the Proposed Acquisition will be satisfied by the issue of 36,409,210 new ordinary shares of 0.1p each in the capital of Onzima ("Ordinary Shares"). It is intended that at the same time the Company will seek to raise approximately GBP3.0 million by way of a placing of new Ordinary Shares to fund development of additional patented reformulations of a wider range of generic drugs, to undertake clinical trials for the Company's reformulation of Sildenafil and for working capital purposes. The Proposed Acquisition will be classified as a reverse takeover under the AIM Rules for Companies and, as a result, is subject to the publication of an admission document in respect of the Company as enlarged by N4 Pharma setting out full details of the Proposed Acquisition and convening a general meeting of the Company where shareholders' approval will be sought for, among other things, the Proposed Acquisition and to change the Company's name to N4 Pharma plc (the "Admission Document"). Onzima is gradually monetising its share portfolio to provide funds for the continued development of N4 Pharma and the costs of the Proposed Acquisition. Following completion of the Proposed Acquisition, its trading division will cease to exist. Onzima has today agreed to increase its loan facility to N4 Pharma from GBP209,000 to GBP309,000. In anticipation of the Proposed Acquisition, the Company has appointed Stockdale Securities Limited as its nominated adviser and broker with immediate effect. It is expected that, subject to the completion of satisfactory due diligence, preparation of the requisite documentation and obtaining shareholders' approval, the Proposed Acquisition will be completed in mid-April 2017 ("Completion"). On Completion, it is expected that new directors will be appointed to the board of Onzima, including Nigel Theobald, the founder and Chief Executive of N4 Pharma, and that Professor Mughal and Gavin Burnell will step down as directors of the Company. It is expected that the temporary suspension of trading on AIM in the Ordinary Shares will remain until Completion. Further announcements will be made in due course. |
Posted at 31/7/2016 17:38 by purchmeisner So in theory Nigel could issue a huge number of new shares to the potentially new vehicle in return for cash? But then he'd have to issue new shares to himself to ensure he has the majority holding? Otherwise he'll be completely diluted too surely.The thing is if this alternative deal gives N4 the funding it needs then I think ONZ share price will rocket even if their holding becomes diluted as not only will they not need to find it they'll still have a decent stake in what could be a £100m company in a few years. |
Posted at 29/7/2016 11:35 by fido Been a busy morning.Very quickly before I set off, many here say that onz can increase their stake in N4. However there are those who consider that onz are already in breach of their investment policy. Catch you later. Is Onzima Ventures breaching it's investing policy? By Gary Newman | Tuesday 8 March 2016 Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article. I’ve been noticing a lot of chatter on Twitter about a small AIM investing company called Onzima Ventures (ONZ), so I decided to take a closer look to see if all the fuss was justified! This company was previously known as Ultima Networks until October 15 last year when it changed its name, having disposed of all of its operating activities and then raised £750,000, before expenses, by issuing 107.1 million shares at 0.7p. Last week it saw its share price rocket when it announced that it had acquired a 49% stake in a private company called N4 Pharma Limited, via the issue of 24.27 million Onzima shares (locked in for two years) plus £41,000 in cash. On the face of it N4 Pharma looks quite interesting as it is in the biotech industry and reformulates existing drugs using it’s patented Cocrys and Nuvac technology platforms, plus founder Nigel Theobald has over 25 years in the industry. As part of the deal Onzima also agreed to provide a loan facility of £209,000 to develop the business, at an annual rate of 5% and repayable after four years, and there has been much excitement on the chat forums about how great N4 and it’s products are – although it is yet to actually have any product approved or ready for market. The main focus seems to be around a faster-acting alternative to existing Viagra, where the patent ran out in 2013, and there have been boasts about this market being potentially worth $4 billion. With that in mind I find it somewhat strange that N4 Pharma has had to turn to a tiny AIM company like Onzima to secure the funding that it needs, as you’d think that potential investors would be crawling all over it if the product was that good! It is hard to find that much information on N4 Pharma as it is privately listed, although its last accounts up to the end of March 2015 did show that it had trade creditors of over £52,000, with just £5,500 in the bank and net liabilities of nearly £37,000. This might suggest that it wasn’t in great financial shape, having only been set up a couple of years or so ago, yet Onzima has paid the equivalent of around £200,000 in cash and shares for it’s 49% stake. Given the costs often associated with biotech and getting a final drug to market, even if it is only in a new form, I have to wonder how much more cash it is going to need in the future, as well as whether bigger companies are going to just stand aside and allow it to grab a share of the Viagra market, or that of any other major drug for that matter! But what also interests me is whether Onzima is adhering to its investing policy, as set out when it changed it’s name and became an investing company. It raised net proceeds of £650,000 from the equity issue, which amounted to its net cash at the time, and its investing policy states that it will seek to invest a minimum of 75% of its deployable capital in the natural resources sector – an area it’s CEO Gavin Burnell (of Globo infamy) knows well from previous directorships in companies such as Magnolia Petroleum (MAGP), plus a number of current ones. Now I can’t help wondering if that leaves Onzima in breach of its investing policy, given that the money potentially loaned to N4 is no longer available to be invested as stated – although in terms of direct investment in N4 the company hasn’t breached the agreed 25% limit for non-natural resources based interests. Aside from this Onzima also invested £50,000 in fellow AIM investment company Glenwick (GWIK) at 0.1p back in December, and seems to have flipped that in circumstances which raised eyebrows (HERE). Onzima shares are currently trading at around 1.1p to buy and that gives a market cap of nearly £1.5 million, which represents a considerable mark-up to it’s actual asset value (given what it has paid for it’s share of N4 you would have to assume that is the current value of that 49% - although selling it to anyone else might not be easy so that is being generous!). There is also a £4 million debt technically due to the company as a result of the disposal of its previous assets, but any repayment of that will only benefit those holding special deferred shares, via any special dividend, which were issued when the capital was reorganised prior to the equity issue at 0.7p. This could well see further spikes in the future, but I would expect the majority of those to be based more on hype than substance, and therefore consider this company to be extremely high risk and not one for novice investors or small PIs to consider risking their money in. Even more so when I think there is the potential for questions to be raised about a possible breach of it’s investing criteria, plus the past few days are probably the first real chance that those 0.7p placees from back in October have had to offload at a profit, given very thin daily volumes for several months! - See more at: |
Posted at 28/7/2016 15:09 by fido In fact given that I have said that Nigel wants the onz share price to rise, it does make you wonder why he does not announce a deal with onz because it would be beneficial for his onz holding. The fact that he does not do that means that he is open to alternative offers, probably as I said above, one that can offer the full investment capital rather than onz handing round the begging bowl all the time. |
Posted at 24/7/2016 21:02 by bigego Great post before K5000, it upset the nasty man!-------- keya5000 24 Jul'16 - 19:52 - 206 of 228 2 0 thoughts below of an associate who holds an interest in ONZ covers the near term drivers very well. We all know this depends on the success of N4 but the main man has been there and done it before. Good chance we will see history repeat itself. I asked Nigel Theobald why he left his previous company. He replied that he left because he thinks he can do better with n4. That's good enough for me. --------- I think the drivers for the ONZ share price catalysed by N4 are (in a very rough chronological order – although as you know it’s all highly uncertain!): -Further patent filings for other potential drugs that can be reformulated b N4’s platforms (although admittedly these will not be major share price drivers, these announcements will help to paint a picture of the range of revenue streams that N4 could enjoy in the longer term) -Results on sildenafil PoC studies -Securing a major pharma as a partner in bringing a reformulated sildenafil to market. Ideally we’ll see the partner entirely funding the development whilst taking a big portion of future revenue share. This process of seeking a partner for sildenafil was commenced three months ago -Securing a major partner for the Cocrys platform as a whole -Grant funding for Nuvac and/or Nuvec platforms (again staves off equity dilution to N4 (and thus to ONZ), something that private investors love). These two appear slightly behind Cocrys in terms of development -Results on further testing of Nuvac/Nuvec platforms -Securing a major partner to fund the further development of these platforms -Announcement of next major product to be developed on the platforms after sildenafil Beyond these specific catalysts, what I really like about the N4 story is: -Nigel’s track record in the space -Nigel’s belief in the potential of the platforms that he has created (as evinced by his share purchases in placings and on the open market) -The business model (circa £3m in total per reformulation of a particular product, and the short time to market (2.5-3 years); which if successful can result in annual sales for any particular product of many tens of millions of £) -The likely route to market via ONZ. An RTO is the very obvious move here, with ONZ enjoying a bargaining chip via its existing loan note (which will likely be made convertible at the time of RTO, along with the issuance of consideration shares for Nigel and a placing of new shares to fund the next two years of ops). I don’t think this will occur until news of a partnership with a major comes, at which point the RTO can be achieved at a materially higher share price -The obvious takeover target that N4 represents (specifically, by Pfizer, given that sildenafil is N4’s first drug it is reformulating. I picture Pfizer taking out all of N4 and first and foremost using the reformulated sildenafil to simply ‘refresh’ I’m also getting increasingly confident that a second (and potentially third) biopharma investment will be made in the near future. The rationale for this is based on: - our CEO hinting at increasing exposure to the space (in the Year End results); - the creation of the two divisions, asset trading and business development (were only one long term investment to be made and held, I feel that the creation of the B.D. division would have been largely pointless); - our directors not having bought stock on the open market. Inside? So news on this front likewise has the potential to act as a significant share price driver for ONZ. I believe cash burn is currently circa £15k per month, so there’s ample leg room before any fundraise is required. Indeed, it would seem that the Asset Trading division is covering all corporate overheads! |
Posted at 24/7/2016 19:52 by keya5000 thoughts below of an associate who holds an interest in ONZ covers the near term drivers very well. We all know this depends on the success of N4 but the main man has been there and done it before. Good chance we will see history repeat itself.I asked Nigel Theobald why he left his previous company. He replied that he left because he thinks he can do better with n4. That's good enough for me. --------- I think the drivers for the ONZ share price catalysed by N4 are (in a very rough chronological order – although as you know it’s all highly uncertain!): -Further patent filings for other potential drugs that can be reformulated b N4’s platforms (although admittedly these will not be major share price drivers, these announcements will help to paint a picture of the range of revenue streams that N4 could enjoy in the longer term) -Results on sildenafil PoC studies -Securing a major pharma as a partner in bringing a reformulated sildenafil to market. Ideally we’ll see the partner entirely funding the development whilst taking a big portion of future revenue share. This process of seeking a partner for sildenafil was commenced three months ago -Securing a major partner for the Cocrys platform as a whole -Grant funding for Nuvac and/or Nuvec platforms (again staves off equity dilution to N4 (and thus to ONZ), something that private investors love). These two appear slightly behind Cocrys in terms of development -Results on further testing of Nuvac/Nuvec platforms -Securing a major partner to fund the further development of these platforms -Announcement of next major product to be developed on the platforms after sildenafil Beyond these specific catalysts, what I really like about the N4 story is: -Nigel’s track record in the space -Nigel’s belief in the potential of the platforms that he has created (as evinced by his share purchases in placings and on the open market) -The business model (circa £3m in total per reformulation of a particular product, and the short time to market (2.5-3 years); which if successful can result in annual sales for any particular product of many tens of millions of £) -The likely route to market via ONZ. An RTO is the very obvious move here, with ONZ enjoying a bargaining chip via its existing loan note (which will likely be made convertible at the time of RTO, along with the issuance of consideration shares for Nigel and a placing of new shares to fund the next two years of ops). I don’t think this will occur until news of a partnership with a major comes, at which point the RTO can be achieved at a materially higher share price -The obvious takeover target that N4 represents (specifically, by Pfizer, given that sildenafil is N4’s first drug it is reformulating. I picture Pfizer taking out all of N4 and first and foremost using the reformulated sildenafil to simply ‘refresh’ I’m also getting increasingly confident that a second (and potentially third) biopharma investment will be made in the near future. The rationale for this is based on: - our CEO hinting at increasing exposure to the space (in the Year End results); - the creation of the two divisions, asset trading and business development (were only one long term investment to be made and held, I feel that the creation of the B.D. division would have been largely pointless); - our directors not having bought stock on the open market. Inside? So news on this front likewise has the potential to act as a significant share price driver for ONZ. I believe cash burn is currently circa £15k per month, so there’s ample leg room before any fundraise is required. Indeed, it would seem that the Asset Trading division is covering all corporate overheads! |
Posted at 22/7/2016 14:14 by bigego Strange way to behave when you are meeting someone next week to sell them the idea of taking on N4???------------------ Tweets & replies DaveD @Dav012d 11m11 minutes ago #ONZ There`s that P word again. When I play the lottery I have the "POTENTIAL" to be a millionaire Just the slight problem of the odds. 0 retweets 0 likes DaveD @Dav012d 14m14 minutes ago #ONZ He done it before he will do it again" Not without a big producer saying YES he won`t Anyone want to flip a coin? 0 retweets 0 likes DaveD @Dav012d 16m16 minutes ago #ONZ HIGH RISK casino stock Talk of a scam No deal No drugs No revenue Little investment capital Reliant on the begging bowl. 0 retweets 0 likes Promoted Tweet Money-Short-Cuts @moneyshortcu Brilliant way to check if you had PPI! Promoted 9 retweets 20 likes DaveD @Dav012d 20m20 minutes ago #ONZ Checked up on a RAMPER lie ie ONZ having 1st option over the rest of N4 Just as I thought, it is a complete lie N4 have many options 0 retweets 0 likes DaveD @Dav012d 2h2 hours ago #ONZ Nigel tweeted spread the N4 word These interviews aim to fan the RAMPERS fire and little more. No deal No drugs No money Ramp & Hype 0 retweets 0 likes DaveD @Dav012d 2h2 hours ago #ONZ Promise the world and deliver NOTHING Some would call that a scam 0 retweets 0 likes DaveD @Dav012d 2h2 hours ago #ONZ Same tired old message as in all the other interviews, almost word for word. Nothing new at all. Time to stop talking & do it 0 retweets 0 likes DaveD @Dav012d 4h4 hours ago #ONZ Question How easy is it going to be for ONZ to raise cash when there are city concerns about a scam. Where will N4 be without funding. 0 retweets 0 likes DaveD @Dav012d 4h4 hours ago #ONZ The time-scales are years away In the meantime N4 have not much capital and need 2-3 million ONZ only have the begging bowl NOT GOOD 0 retweets 0 likes DaveD @Dav012d 4h4 hours ago #ONZ Pie in the sky figures like the world is going to stand aside and let N4 take market share. Meanwhile back in the real world....... 0 retweets 0 likes DaveD @Dav012d 4h4 hours ago #ONZ , Justin asked the same tired old questions as he did on his pod cast and got the same tired old answers. Back to sleep. 0 retweets 0 likes DaveD @Dav012d 4h4 hours ago #ONZ Patents are not the same as "working on" so N4 have 1 drug that is 2 years away IFthey get a deal, At the moment they have NOTHING 1 retweet 0 likes DaveD @Dav012d 4h4 hours ago #ONZ RAMPERS said N4 were already working on 10-20 other drugs The interview states they will only file for patents on 8-9 in the next year 0 retweets 0 likes DaveD @Dav012d 4h4 hours ago #ONZ Fact is that Nigel has NO DEAL Very little money Only has ONZ with its begging bowl. Not the best of odds is it. 0 retweets 0 likes DaveD @Dav012d 4h4 hours ago #ONZ Nigel needs another 2-3 million to bring viagra to market. Where`s that money coming from and how`s he doing it without a JV deal. 0 retweets 0 likes Promoted Tweet Funded Solar Panels @GetFundedSol Homeowner? Check if your Postcode Qualifies for Fully Funded Solar Panels. hxxp://www.fundedsol Promoted 20 retweets 48 likes DaveD @Dav012d 5h5 hours ago #ONZ Oh dear how embarrassing for Nigel. On the plus side, a few more of the RAMPERS lies shown for what they are, Same tired old message. 0 retweets 1 like DaveD @Dav012d 6h6 hours ago #ONZ Nigel should walk the walk NOT talk the talk. If its that good then make it good NOT spend all your time at interviews talking about it 0 retweets 0 likes DaveD @Dav012d 6h6 hours ago #ONZ I can remember David Robson spending all his time at interviews talking of multi baggers. His company all but went bust. Talk is cheap 0 retweets 0 likes DaveD @Dav012d 6h6 hours ago #ONZ Lets compare Nigel`s Momentous interview with all the others he`s done and see if anyone can spot the difference other than the date 0 retweets 0 likes |
Posted at 20/7/2016 11:29 by fido I said before that Nigel needed the share price to rise quickly for reasons I am not going to discuss. The share price has failed to perform as would be hoped for and thus Nigel has tried to support the price with share purchases. This tactic has failed and the price is heading back down, fuelled by people selling as a result of non performance and being fed up of being pumped full of pie in the sky dreams when on the ground it is like watching paint dry.People are getting very tired of onz EVEN WITH the RAMPING machine in full swing and will sell accordingly. For the above reasons I believe Nigel will find my alternative option very appealing. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
